

In-house Development programs

Early-stage diagnostic and therapeutic pipeline

Indication	Target	Candidate	Type	Radionuclide	Project	Discovery	Pre-clinic	Regulatory	First-In-Human	Phase 1	Partner	
FAP Expressing Tumors	Fibroblast Activation Protein (FAP)	DualFAPi-7	PET	¹⁸ F	18F-DualFAPi						 innovative health initiative  Co-funded by the European Union European Innovation Council  Co-funded by the European Union European Innovation Council  Co-funded by the European Union  innovative health initiative  Co-funded by the European Union	
		DualFAPi-5	γ	¹²³ I	123I-DualFAPi							
			β ⁻	¹³¹ I	131I-DualFAPi							
			α	²¹¹ At	211At-DualFAPi							
Prostate cancer	PSMA	PSMA-TBD	PET	¹⁸ F	18F-FlutraProst						eurostars™	
NETs	SSTR/ Octreotate	OCT-TBD	PET	¹⁸ F	18F-FlutraTate						 innovative health initiative  Co-funded by the European Union 	
			α	²¹¹ At	211At-AstraTate							

Diagnostic

Therapeutic

Platform Partnerships

Early-stage diagnostic and therapeutic pipeline

Indication	Target	Candidate	Type	Radionuclide	Project	Discovery	Pre-clinic	Regulatory	First-In-Human	Phase 1	Partner
Pancreatic cancer	$\alpha\beta6$ integrin	TVX-01	PET	^{18}F	^{18}F -FlutaHexin						
Undisclosed	Undisclosed	3BP-TBD	α	^{211}At	3BP (^{211}At)						
Epithelial-derived cancers	CD44v6	AmbiTag	β^-/α	$^{131}\text{I}/^{211}\text{At}$	AmbiTag for Pretargeting						  

Diagnostic

Therapeutic